Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-09-06 18:20:36
Oslo, 6 September 2021
In accordance with the authorisation granted and the remuneration policy adopted
by the Annual General Meeting 28 May 2021, the Board of Directors of PCI Biotech
Holding ASA ("PCI Biotech") has awarded a total of 485,000 share options to key
employees. Each share option gives the right to subscribe for or acquire one
share per option (after PCI Biotech's choice), at a strike price of NOK 19.41,
equal to the volume weighted average share price (VWAP) for the last 5 days of
trade prior to the grant date. The share options are granted without
consideration and are subject to service based vesting conditions, with a three
year vesting term and one third vested each year. The share options are lapsing
in Q3 2026. Further details about the share option program are described in PCI
Biotech's remuneration policy, available on https://www.pcibiotech.no/s/PCI-
Biotech-Remuneration-Policy-6-May-2021.pdf.
To ensure long term ownership by executive management, shares obtained by
exercise of share options shall be held for at least one year, except shares to
be sold immediately to cover transaction costs and tax under a so-called cash
less exercise. Through the long-term incentive program the board expects members
of the executive team to build up and maintain share ownership with a market
value equal to at least one-year gross base salary, before any shares may be
sold.
Of the 485,000 share options, 340,000 share options were allotted to the
following primary insiders:
70,000 share options were allotted to Per Walday, CEO. After the allotment, Per
Walday holds a total portfolio of 295,000 unexercised share options and 72,700
shares.
60,000 share options were allotted to Amir Snapir, CMO. After the allotment,
Amir Snapir holds a total portfolio of 150,000 unexercised share options and 0
shares.
50,000 share options were allotted to Ronny Skuggedal, CFO. After the allotment,
Ronny Skuggedal holds a total portfolio of 190,000 unexercised share options and
55,000 shares.
40,000 share options were allotted to Anders Høgset, CSO. After the allotment,
Anders Høgset holds a total portfolio of 190,000 unexercised share options and
64,800 shares.
40,000 share options were allotted to Ludovic Robin, CBO. After the allotment,
Ludovic Robin holds a total portfolio of 130,000 unexercised share options and
0 shares.
40,000 share options were allotted to Lucy Wabakken, CDO (acting). After the
allotment, Lucy Wabakken holds a total portfolio of 160,000 unexercised share
options and 0 shares. Her related parties holds 10,008 shares.
40,000 share options were allotted to Kristin Eivindvik, CDO. After the
allotment, Kristin Eivindvik holds a total portfolio of 110,000 unexercised
share options and 25,200 shares.
Primary insider notifications pursuant to the market abuse regulation article
19 are attached.
The current authorisation, as of 28 May 2021, allows for a total of 2,790,000
share options, of which 1,615,000 now have been granted by the Board of
Directors.
For more information, please contact:
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429
This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and to section 5-12 of the Norwegian
Securities Trading Act.